logo-loader

Crescita Therapeutics leverages its unique drug delivery systems and a strong pipeline for growth

Published: 13:24 22 Jun 2018 EDT

Crescita Therapeutics Inc. (TSX:CTX) executive chairman of the Board Dan Chicoine talks to Proactive about the rapid growth of its prescription dermatology lines and how it is leveraging its unique drug delivery systems to support growth of its product lines.

He also discussed how the company deals with intense competition in the skincare industry.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 18 minutes ago